| Ding, Xueying |
MIT-AIR, NCT06568445: Maintenance at Initial Treatment With Sequential Anti-Inflammation Reliever Therapy |
|
|
| Not yet recruiting | 4 | 90 | RoW | Maintenance at initial treatment sequential as-needed therapy with inhaled budesonide-formoterol(Symbicort 160/4.5) ®）, maintenance at initial treatment sequential as-needed therapy group, as-needed therapy with inhaled budesonide-formoterol (Symbicort 160/4.5) ®）, As-needed therapy group | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Bronchial Asthma | 04/27 | 09/27 | | |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05795920: Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer |
|
|
| Recruiting | 2 | 92 | RoW | Utidelone injection in combination with gemcitabine, UTD1 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Pancreatic Neoplasms | 07/24 | 09/25 | | |
NCT05841771: Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies. |
|
|
| Recruiting | 2 | 78 | RoW | Venetoclax, BCL-2 inhibitor, Azacitidine or decitabine, Hypomethylating Agent | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Hypomethylating Agent, Venetoclax, Myeloid Malignancy | 12/24 | 12/25 | | |
NCT06270030: Safety, Tolerability and Pharmacokinetics of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Chinese With Presbyopia |
|
|
| Completed | 1 | 21 | RoW | LNZ101 (Aceclidine /Brimonidine) ophthalmic solution, LNZ100 (Aceclidine) ophthalmic solution, Placebo (Vehicle) ophthalmic solution | Ji Xing Pharmaceuticals (Shanghai) Co., Ltd., LENZ Therapeutics, Inc | Presbyopia | 04/24 | 04/24 | | |
NCT06604949: A Study of Single Dose of LP-003 in Healthy Adult Subjects |
|
|
| Not yet recruiting | 1 | 12 | RoW | LP-003 200mg, Placebo | Longbio Pharma, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Chronic Spontaneous Urticaria | 11/26 | 12/26 | | |
NCT06023095: A Study of LY3502970 in Chinese Participants With Obesity or Are Overweight With Weight-related Comorbidities |
|
|
| Completed | 1 | 24 | RoW | LY3502970, Placebo | Eli Lilly and Company | Overweight, Obesity | 07/24 | 07/24 | | |
| Recruiting | 1 | 50 | RoW | 626, SSGJ-626, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Healthy Subjects (HS) | 06/25 | 10/25 | | |
